• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • RVU Search
    • NPI Registry Lookup
  • Pharma
  • AI News
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • RVU Search
    • NPI Registry Lookup
  • Pharma
  • AI News
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: Insulin Efsitora is Noninferior to Degludec in Type 2 Diabetes without Previous Insulin Treatment

byAstrid BradshawandAlisha Yi
September 25, 2024
in StudyGraphics
Reading Time: 1 min read
0
Share on FacebookShare on Twitter

Click here to read this study in NEJM. 

©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

RELATED REPORTS

Swedish study reports low vision loss risk with GLP-1RAs

GLP-1RAs may increase ischemic optic neuropathy risk

GLP-1RAs showed no advantage for basal insulin discontinuation

Tags: Glycated hemoglobinglycated hemoglobin levelsinsulininsulin efsitoraT2DT2DMtype 2 diabetesType 2 Diabetes Mellitus
Previous Post

Adaptimmune’s Afami-cel is the first FDA-approved T-cell receptor therapy for synovial sarcoma

Next Post

Ticagrelor monotherapy reduces bleeding risk compared to dual antiplatelet therapy for patients following coronary stenting

RelatedReports

Type 2 diabetes associated with reduction in disability-free life years
Endocrinology

Swedish study reports low vision loss risk with GLP-1RAs

July 13, 2026
Intrapartum serum prolactin may predict risk of postpartum diabetes
Endocrinology

GLP-1RAs may increase ischemic optic neuropathy risk

July 13, 2026
Endocrinology

GLP-1RAs showed no advantage for basal insulin discontinuation

July 13, 2026
Exercise improves aromatase inhibitor-induced arthralgia in breast cancer survivors
Chronic Disease

Resistance training is associated with lower risk of type 2 diabetes

July 2, 2026
Next Post
Drug-coated balloons are noninferior to drug-eluting stents for treatment of small vessel coronary artery disease

Ticagrelor monotherapy reduces bleeding risk compared to dual antiplatelet therapy for patients following coronary stenting

#VisualAbstract Telehealth vs In-Person Early Palliative Care for Patients with Advanced Lung Cancer

#VisualAbstract Telehealth vs In-Person Early Palliative Care for Patients with Advanced Lung Cancer

#VisualAbstract: Perioperative Durvalumab with Neoadju-vant Chemotherapy Improved Survival in Operable Bladder Cancer

#VisualAbstract: Perioperative Durvalumab with Neoadju-vant Chemotherapy Improved Survival in Operable Bladder Cancer

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • All-oral chemotherapy regimen tolerable and efficacious for newly diagnosed acute myeloid leukemia
  • Enzalutamide (Xtandi) and abiraterone (Zytiga) may have similar effectiveness in metastatic castration-sensitive prostate cancer
  • Intermittent metformin (Glucophage) is non-inferior to continuous metformin for prediabetes in post-partum women with prior gestational diabetes mellitus
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • RVU Search
    • NPI Registry Lookup
  • Pharma
  • AI News
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.